← Back

NVONovo Nordisk

$43.07-2.14%Real quote · delayedPharmaPharma & biotech · 16 peers →

🏛️ Company factsSEC filings + FINRA official data

short activity within its normal range.

Short volume

37.9%

20d avg 41.2% · normal

No SEC filings for this ticker (non-US filer or newly listed)

Expectation reliability Medium · 62/100

Nasdaq analyst consensus · the pre-news baseline

Next quarter (Sep 2026) consensus$0.80Estimate range $0.74 ~ $0.86 · 5 analystsRevisions (4w):↑1

History: actual vs consensusavg +20%

The takeaway

This company habitually beats by +20% — the next report has to clear that bar to count as good news.

Analyst estimates, not our forecast · not investment advice

0 direct · 2 2nd-order · 0 thematic

Ranked by impact strength · strength = estimated move × freshness decay (shorter-lived effects decay faster)

#1▼0.29%2nd-order10% Move Ahead? Ross Gerber Reveals What He's Buying Now2d ago
As LLY's chief rival in the GLP-1 weight-loss drug market, incremental sentiment and capital flowing toward LLY could marginally divert attention from Novo Nordisk
Impact chain →
Also named: LLY · MU · NVDA · 000660.KS · NFLX · TTWO
#2▼0.18%2nd-order3 Things That Matter Most for Eli Lilly Now14d ago
By highlighting Lilly's competitive edge in GLP-1 drugs, the article indirectly underscores market-share pressure on rival Novo Nordisk.
Impact chain →
Also named: LLY · UNH

Drag to pan, scroll to zoom · real daily bars and volume

The 26 engine calls on this chart (hit / miss / pending) are Pro — price and volume only for now▂ volume

📜 Call history (newest first

🔒 Pro only

26 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view

🔒 Pro only

Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.